Precision Medicine and PET/Computed Tomography in Melanoma

Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup melanoma patients. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology, have revolutionized the management and outcome of patients with metastatic melanoma. Positron Emission Tomography (PET) imaging plays an important role in noninvasively assessing the tumor biologic behavior, complementary to traditional tissue biomarkers, with the goal of guiding individualized treatment, and assessing response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy, and their implications for functional PET imaging